Landec/$LFCR
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Landec
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
Ticker
$LFCR
Sector
Primary listing
Industry
Life Sciences Tools and Services
Headquarters
Employees
524
Website
Landec Metrics
BasicAdvanced
$259M
-
-$1.49
0.80
-
Price and volume
Market cap
$259M
Beta
0.8
52-week high
$8.85
52-week low
$3.68
Average daily volume
189K
Financial strength
Current ratio
2.706
Quick ratio
1.256
Long term debt to equity
264.507
Total debt to equity
272.869
Interest coverage (TTM)
-0.54%
Profitability
EBITDA (TTM)
-3.488
Gross margin (TTM)
33.45%
Net profit margin (TTM)
-34.27%
Operating margin (TTM)
-9.22%
Effective tax rate (TTM)
0.11%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-3.10%
Return on equity (TTM)
-83.58%
Valuation
Price to revenue (TTM)
1.783
Price to book
116.28
Price to tangible book (TTM)
-16.35
Price to free cash flow (TTM)
-21.382
Free cash flow yield (TTM)
-4.68%
Free cash flow per share (TTM)
-0.327
Growth
Revenue change (TTM)
7.23%
Earnings per share change (TTM)
124.67%
3-year revenue growth (CAGR)
-1.19%
10-year revenue growth (CAGR)
-13.02%
3-year earnings per share growth (CAGR)
-11.91%
10-year earnings per share growth (CAGR)
11.33%
What the Analysts think about Landec
Analyst ratings (Buy, Hold, Sell) for Landec stock.
Landec Financial Performance
Revenues and expenses
Landec Earnings Performance
Company profitability
Landec News
AllArticlesVideos
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Accesswire·2 months ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out
Accesswire·2 months ago
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Landec stock?
Landec (LFCR) has a market cap of $259M as of August 01, 2025.
What is the P/E ratio for Landec stock?
The price to earnings (P/E) ratio for Landec (LFCR) stock is 0 as of August 01, 2025.
Does Landec stock pay dividends?
No, Landec (LFCR) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Landec dividend payment date?
Landec (LFCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Landec?
Landec (LFCR) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.